The giveaway was in the 'PPMO delivery deep into the brain' ann in April
Building off this promising proof-of-concept data, PYC is scaling up discovery efforts to ultimately enable clinical assessment of a promising PPMO drug candidate for a neurodegenerative condition. The Company remains on track to name a CNS drug candidate in 2021 and in parallel, PYC intends to further optimise its delivery technology for CNS administration including assessing both efficacy and safety of PYC’s PPMO technology in larger animals.
combined with today's ann:
This drug candidate has potential application in patient subgroups in other diseases with underlying mitochondrial dysfunction including glaucoma, Parkinson’s Disease and Alzheimer’s Disease
There will be an independent ann solely about thsi topic in the second half of the year, as mentioned in the April ann.
We had a hint at that today in our announcement.
all IMO
PYC Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)